On December 29, China Biopharmaceutical (01177) issued an announcement stating that the Group's independently developed Class 1 innovative drug...TQH3906, a "TYK2/JAK1JH2 allosteric inhibitor," has recently completed its Phase II clinical trial for moderate to severe plaque psoriasis. Results showed that all dose groups of TQH3906 demonstrated good safety and tolerability, and met the primary endpoint of the Phase II study.

The study enrolled 209 patients, including a placebo group and five different TQH3906 dose groups, with oral administration once daily.

In terms of efficacy, TQH3906 showed a good dose-response relationship. At the recommended phase 2 dose, after 12 weeks of treatment, the PASI75 response rate exceeded 90% and the PASI90 response rate exceeded 70%, which was significantly better than the PASI75 and PASI90 response rates in the placebo group (approximately 10% and 5%, respectively).

In terms of safety, TQH3906 has a good overall safety profile, with the overall incidence of adverse events comparable to that of the placebo group, and the vast majority of adverse events being grade 1-2 in severity. In the future, the Group will continue to explore new indications for TQH3906 in multiple autoimmune and dermatological fields, including inflammatory bowel disease and psoriatic arthritis.

https://finance.eastmoney.com/a/202512293604196213.html